Neuspera Medical Reveals Promising 12-Month Trial Results for New Neuromodulation System
Neuspera Medical, Inc., a pioneer in integrated neuromodulation technologies, has unveiled the results of its 12-month pivotal trial for its innovative integrated sacral neuromodulation (iSNM) system aimed at treating urinary urge incontinence (UUI). According to the recent findings, disclosed at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction’s Winter Meeting, a remarkable 94% of trial participants reported substantial relief from symptoms with zero serious adverse events linked to the device.
The trial involved 128 patients implanted with the Neuspera SNM System, which yielded particularly impressive results. Specifically, 81% of participants were classified as super-responders, reporting a reduction of at least 75% in their UUI episodes. Furthermore, 43% of participants experienced complete elimination of their UUI episodes, a defining moment for many who suffer from this often-debilitating condition.
Dr. Andrea Pezzella from Southern Urogynecology Wellness and Aesthetics, who presented the trial results, emphasized the importance of sustained effectiveness for patients. The data demonstrated not only the system's long-term efficacy but also promising preliminary results from a reduced therapy regimen that suggested just 30 minutes of daily stimulation could provide symptom relief comparable to longer therapy sessions. This could represent a significant advancement in patient comfort and therapy adherence, addressing a common concern while maintaining treatment effectiveness.
Neuspera's device addresses existing issues associated with traditional sacral neuromodulation (SNM) systems. The company’s design eliminates the need for battery replacements and reduces the risk of infections that can accompany more conventional approaches. According to Neuspera Medical's CEO, David Van Meter, the comprehensive results underscore the advanced safety profile and efficacy of the iSNM system, prioritizing the patient experience along with clinical outcomes.
Neuspera’s integrated SNM device features a miniature neurostimulator positioned near the sacral nerve, activated through an external battery-powered disc that can be easily worn against the lower back. This modern setup allows for wireless charging when not in use, akin to a smartphone, and emphasizes the removal of complications related to implanted batteries.
Following these promising findings, Neuspera is set to present additional research at the upcoming American Urological Association Annual Meeting, further exploring the benefits of reduced therapy durations in patients. The company's commitment to advancing the treatment of urinary urge incontinence signals a notable step forward in the realm of neuromodulation therapies, potentially changing the landscape for patients suffering from this condition.
As the trial results suggest a solid safety record—no serious device-related adverse events reported—the focus now shifts toward further validation of this therapy regimen and its availability to a broader patient population. With the FDA’s approval of the iSNM system in June 2025, Neuspera Medical is poised to transform the standards of care for those experiencing urinary urge incontinence and improve their quality of life.
The trial involved 128 patients implanted with the Neuspera SNM System, which yielded particularly impressive results. Specifically, 81% of participants were classified as super-responders, reporting a reduction of at least 75% in their UUI episodes. Furthermore, 43% of participants experienced complete elimination of their UUI episodes, a defining moment for many who suffer from this often-debilitating condition.
Dr. Andrea Pezzella from Southern Urogynecology Wellness and Aesthetics, who presented the trial results, emphasized the importance of sustained effectiveness for patients. The data demonstrated not only the system's long-term efficacy but also promising preliminary results from a reduced therapy regimen that suggested just 30 minutes of daily stimulation could provide symptom relief comparable to longer therapy sessions. This could represent a significant advancement in patient comfort and therapy adherence, addressing a common concern while maintaining treatment effectiveness.
Neuspera's device addresses existing issues associated with traditional sacral neuromodulation (SNM) systems. The company’s design eliminates the need for battery replacements and reduces the risk of infections that can accompany more conventional approaches. According to Neuspera Medical's CEO, David Van Meter, the comprehensive results underscore the advanced safety profile and efficacy of the iSNM system, prioritizing the patient experience along with clinical outcomes.
Neuspera’s integrated SNM device features a miniature neurostimulator positioned near the sacral nerve, activated through an external battery-powered disc that can be easily worn against the lower back. This modern setup allows for wireless charging when not in use, akin to a smartphone, and emphasizes the removal of complications related to implanted batteries.
Following these promising findings, Neuspera is set to present additional research at the upcoming American Urological Association Annual Meeting, further exploring the benefits of reduced therapy durations in patients. The company's commitment to advancing the treatment of urinary urge incontinence signals a notable step forward in the realm of neuromodulation therapies, potentially changing the landscape for patients suffering from this condition.
As the trial results suggest a solid safety record—no serious device-related adverse events reported—the focus now shifts toward further validation of this therapy regimen and its availability to a broader patient population. With the FDA’s approval of the iSNM system in June 2025, Neuspera Medical is poised to transform the standards of care for those experiencing urinary urge incontinence and improve their quality of life.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.